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FMDAbstract Background: Patients with rheumatoid arthritis (RA) have increased coronary athero-
sclerosis possibly related to several factors including insulin resistance. Anti-CCP antibodies are
highly speciﬁc for RA but their association with cardiovascular morbidity has not been examined
by enough studies.
Aim: The aimof this studywas to evaluate the role of anti ccp antibodies and IR for detection of early
and sub-clinical atherosclerosis in RA patients.
Subjects and methods: 56 RA patients and 19 age and sex matched healthy subjects were included in
the present study. All patients and controls were subjected to full history, clinical examination, and
laboratory investigations (including CBC, ESR, high sensitive CRP, rheumatoid factor and lipid pro-
ﬁle). All patients were also subjected tomeasurement of intima-media thickness (IMT) of both carotid
arteries as well as the ﬂow mediated dilatation (FMD) of brachial artery. Also, measurements of IR
(by HOMA 2) and anti-CCP were done for all subjects.
Results: IMTwas signiﬁcantly increased (P= 0.01) andFMDsigniﬁcantly decreased (P= 0.001) in
RA patients than controls in spite of the absence of signiﬁcant differences in traditional atheroscle-
rotic risk factors. Both IR and anti-CCP (which are signiﬁcantly increased in RA compared to con-
trols, P= 0.02 and 0.001 respectively) were signiﬁcantly positively correlated to IMT (P= 0.009
and 0.001 respectively) and negatively correlated to FMD (P= 0.0005 and 0.005 respectively).
110 M.a.k.a. wahab et al.Conclusion: IR and anti-CCP may be helpful in the early detection of subclinical atherosclerosis in
RA patients.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with rheumatoid arthritis (RA) have increased coro-
nary atherosclerosis possibly related to increased prevalence
of visceral adiposity, insulin resistance, and metabolic syn-
drome.1 Insulin resistance (IR) is the condition in which nor-
mal amounts of insulin are inadequate to produce a normal
response from fat, muscle and liver cells. Roughly half of IR
is genetically determined and half is acquired (one quarter
from obesity and one quarter from physical inactivity).2,3
IR is associated with atherosclerotic risk factors which
included in the metabolic syndrome such as hypertension,
hyperlipidemia, and obesity that subsequently accelerate the
development and progression of atherosclerosis; it was
reported that there was peripheral IR associated with carotid
as well as coronary artery atherosclerosis in RA patients and
related to disease activity in absence of metabolic syndrome
features; so impaired insulin sensitivity further predicts cardio-
vascular disease independent of other metabolic syndrome
features.4,5
Some immunological markers, such as rheumatoid factor
and anti-CCP are more encountered in RA with extra-articular
manifestations, and anti-CCP antibodies have been shown to
be highly speciﬁc for RA and are more predictors, (even stron-
ger) of disease severity and activity than rheumatoid factor.
But until now, their association with cardiovascular morbidity
has not been examined by enough studies.6
2. Patients and methods
Fifty-six (56) RA patients were included in the present study:
forty (40) women and sixteen (16) men, and their age ranged
from twenty (21) to forty-nine (49) years and disease duration
ranged from six months to ﬁfteen years. Patients were diag-
nosed according to the American College of Rheumatology
(ACR) 1987 revised criteria for the classiﬁcation of rheumatoid
arthritis (Appendix A). Nineteen (19) age and sex matched
healthy subjects were recruited as controls.
Exclusion criteria: Known atherosclerotic complications
such as stroke and myocardial infarction: those undergoing
hemodialysis, peripheral vascular disease, malignancy, or
infections, and hypertensive and diabetic patients were
excluded.
All patients and controls were subjected to full history tak-
ing, clinical examination, and laboratory investigations
(including CBC, ESR, high sensitive CRP, rheumatoid factor
and lipid proﬁle). All patients were also subjected to measure-
ment of intima-media thickness of both carotid arteries as well
as the ﬂow mediated dilatation of brachial artery.
Calculation of insulin resistance by HOMA2-IR method:
UBI MAGIWEL insulin quantitative kit is a solid phase
enzyme linked immunosorbent assay (ELISA) and this test is
designed for in vitro quantitative measurement of insulin in
human serum and plasma.IR was calculated according to the HOMA homeostasis
model as [serum insulin (lU/ml) · plasma glucose (mmol/L)/
22.5].7 The output of the HOMA2 model was calibrated to
give a beta-cell function of 100% and an IR of 1 as normal.
Therefore, values were considered abnormal when HOMA2-
IR was > 1.8
Anti-CCP: CCP IgG ELISA is a semi-quantitative enzyme
linked immunosorbent assay for the detection of IgG anti-CCP
in patient sera. The newer version of anti-CCP (anti-CCP2)
was used because it is more sensitive.9 Less than or equal to
5 u/ml = Negative and more than 5 u/ml = Positive.9
3. Carotid ultrasound measurements
Carotid ultrasound evaluation was done for all subjects in this
study to determine the intima media thickness (IMT) and to
detect carotid plaques with the high-resolution B-mode ultra-
sound equipment Medison 9900 multibeam 30 UL (Korea)
equipped with liner probe (7.5 MHz) with the use of a stan-
dardized protocol.10
Individuals were investigated in the supine position and
IMT of the far wall was evaluated as the distance between
the luminal–intimal interface and the medial-adventitial inter-
face about 1.5 cm proximal to the carotid bifurcation. IMT
measurements were obtained from 4 contiguous sites at
2 mm intervals, and calculation of the average was done.
The mean IMT (the mean of both right and left side) was
assessed. At the same time the maximum IMT (the highest
value either right or left) was also assessed. IMT is consider
abnormal if >.072 cm.11
Plaques: These were deﬁned as focal widening relative to
adjacent segments, with protrusion into the lumen of calciﬁed
or noncalciﬁed material.12 All ultrasound measurements were
performed by the same examiner who was unaware of subject
characteristics.
Endothelial function: To assess endothelial function non-
invasively with B-mode ultrasound, conduit vessel endothe-
lium-dependent vasodilatation was induced by reactive hyper-
emia, while endothelium-independent vasodilatation was
induced by administration of sublingual nitroglycerine (glyc-
eryl trinitrate (GTN)).13
Measurements were made of changes in the diameter of the
brachial artery using color duplex Doppler ultrasound. The
ultrasound examination was performed in quiet room at tem-
perature between 21 C and 32 C. Subjects rested in a supine
position for 15 min before examination. A B-mode scan was
obtained of the right brachial artery in longitudinal section.
A resting measurement was taken and called pre-ﬂow mediated
dilatation (pre FMD), and a pneumatic cuff was then inﬂated
to a pressure of 200 mmHg for 5 min, then the diameter of
the artery was recorded again 45–60 s after deﬂation (post
FMD). A period of 15 min was allowed for recovery before
testing for endothelium-independent relaxation. A repeat base-
line measurement of the diameter was before a 400 lg dose of
25.00%
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chial artery diameter was again measured 3–4 min after the
GTN was given (post GTN).14
A single investigator performed all imaging and analysis,
blinded to the subject’s disease.
FMD, GTN, and dilatation ratio were calculated as
follows:
FMD= (Post FMD – Pre FMD)/Pre FMD · 100.
GTN= (Post GTN – Pre GTN)/Pre GTN · 100.
Dilatation ratio = FMD/GTN · 100.
3.1. Statistical analysis
Data were coded, entered and analyzed by the statistical
Package for the Social Sciences (SPSS for windows version
11.0). Parametric data were reported as mean ± SD, while
non-parametric data were expressed as number and percentage.
A Student t test and the chi-squared (v2) test were used to com-
pare variables for testing statistical signiﬁcant difference
between two groups and the differences were considered signiﬁ-
cant at a two-tailed p 6 0.05 andMann–Whitney Test was used
to study the correlations of the nonparametric variables.
4. Results
There is no signiﬁcant difference in age and sex between both
groups (Table 1).Table 1 Demographic data of patients and control group.
Patients (N= 56) Control (N= 19) P-value
Age Range 21–49 22–49 0.350
Mean ± S.D. 36.50 ± 7.22 34.6 ± 8.22
Sex Male 9 (16.07%) 3 (15.8%) 0.977
Female 47 (83.92%) 16(84.2%)
Table 2 Comparison of endothelial function in RA patients and co
RA patie
Pre.fmd (average) Mean ± SD 3.69 ±
Post.fmd (average) Mean ± SD 4.32 ±
Fmd % Mean ± SD 17.30 ±
Pre.GTN (average) Mean ± SD 3.71 ±
Post.GTN (average) Mean ± SD 4.63 ±
GTN.dilatation % Mean ± SD 24.87 ±
Dilatation ratio Mean ± SD 0.71 ±
FMD= ﬂow mediated dilatation, GTN= glyceryl trinitrate.
Table 3 Comparison of ultrasonographic duplex ﬁndings in RA pa
RA patients
Mean IMT Mean ± SD 0.057 ± 0.0
Lt. IMT Mean ± SD 0.057 ± 0.0
Rt. IMT Mean ± SD 0.068 ± 0.0
Maximum Mean ± SD 0.0597 ± 0.0
IMT= intima media thickness.Carotid IMT was signiﬁcantly increased in RA patients
compared to controls while there is signiﬁcant decrease in
FMD and dilatation ratio in RA patients compared to con-
trols (Tables 2 and 3, Fig. 1).
The prevalence of insulin resistance is signiﬁcantly
increased in patients than in controls. Furthermore, there is
signiﬁcant increase in insulin resistance level as well as anti-
CCP in rheumatoid arthritis compared to controls (Tables 4
and 5, Fig. 2).
Table 5 and Fig. 2 showed that there is signiﬁcant increase
in ESR and CRP (acute phase reactant) in rheumatoid patients
compared to controls
Results of this study revealed that there is no signiﬁcant dif-
ference in traditional atherosclerotic risk factors between
patients and controls (Table 6).
Results of the current study revealed signiﬁcant correlation
between insulin resistance and carotid IMT (Table 7).
Also, there is signiﬁcant negative correlation between insu-
lin resistance and ﬂow mediated dilatation and dilatation ratio
in rheumatoid patients (Table 8).ntrols.
nts (n= 56) Controls (n= 19) P
0.51 3.9 ± 0.49 0.121
0.60 5.11 ± 0.52 0.0001
7.72 28.52 ± 10.11 0.001
0.54 3.91 ± 0.49 0.150
0.72 4.89 ± 0.62 0.131
9.02 25.72 ± 9.67 0.727
0.261 1.078 ± 0.189 0.0001
tients and controls.
(n= 56) Controls (n= 19) P
16 0.050 ± 0.007 0.01
16 0.049 ± 0.008 0.01
87 0.0495 ± 0.0869 0.11
17 0.0526 ± 0.008 0.02
0.00%
5.00%
10.00%
15.00%
20.00%
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Figure 1 Prevalence of premature atherosclerosis in RA patients
and controls.
Table 4 Prevalence of insulin resistance in rheumatoid
arthritis patients and controls.
Patients
(N= 56)
Controls
(n= 19)
P
Presence of insulin resistance 51 (91.1%) 7 (36.8%) 0.005
HOMA2-IR= homeostasis model assessment, IR = insulin
resistance.
Table 5 Laboratory features of RA patients and controls.
RA patient (n= 56) Controls (n= 19)
Mean ± SD Mean ± SD P
ESR (mm/h) 40.82 ± 42.27 16.26 ± 8,74 0.0001
US-CRP 70.4 ± 61.71 0.54 ± 0.64 0.0001
Anti ccp 85.11 ± 81.98 0.86 ± 0.46 0.0001
HOMA2-IR 87.96 ± 270 5.34 ± 8.4 0.02
ESR= erythrocyte sedimentation rate, HOMA2-IR = homeosta-
sis model assessment, IR = insulin resistance.
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Figure 2 Comparison between IR, Anti-ccp and Us-CRP in RA
patients and controls.
Table 6 Atherosclerotic risk factors in rheumatoid patients
and controls.
RA patient (n= 56) Controls (n= 19)
Mean ± SD Mean ± SD P
FBS (mg%) 90.7 ± 17.43 88.42 ± 10.27 0.5
Total
cholesterol (mg/dl)
166.25 ± 30.76 170.42 ± 36.65 0.63
Triglycerides
(mg/dl)
90.70 ± 30.72 81.42 ± 26.8 0.22
HDL (mg/dl) 42.8 ± 3.4 42.37 ± 4.4 0.63
LDL (mg/dl) 114.45 ± 33.4 8 122.26 ± 35.41 0.406
Table 7 Correlation between insulin resistance and Ultra-
sonographic duplex ﬁndings in RA patients.
Duplex ﬁndings IR
(r) P
Rt IMT 0.051 0.71
Lt. IMT 0.266 0.005
Mean IMT 0.344 0.009
Maximum IMT 0.344 0.009
IMT= intima media thickness, (r) = correlation coefﬁcient.
Table 8 Correlation between insulin resistance and endothe-
lial function in RA patients.
Endothelial function IR
(r) P
Pre.fmd (average) 0.139 0.308
Post.fmd (average) 0.091 0.04
Fmd % 0.403 0.005
Pre.GTN (average) 0.141 0.23
Post.GTN (average) 0.039 0.715
GTN dilatation % 0.123 0.301
Dilatation ratio 0.112 0.012
(r) = correlation coefﬁcient, FMD= ﬂow mediated dilatation,
GTN= glyceryl trinitrate.
Table 9 Correlation between anti-CCP and Ultrasonographic
duplex ﬁndings in RA patients.
Duplex ﬁndings Anti-CCP
(r) P
Rt IMT 0.24 0.06
Lt. IMT 0.47 0.0001
Mean IMT 0.45 0.001
Maximum IMT 0.46 0.0001
Table 10 Correlation between anti-CCP and endothelial
function in RA patients.
Endothelial function Anti-CCP
(r) P
Pre.fmd (average) 0.27 0.23
Post.fmd (average) 0.22 0.02
Fmd % 0.09 0.005
Pre.GTN (average) 0.26 0.39
Post.GTN (average) 0.17 0.72
GTN dilatation % 0.29 0.31
Dilatation ratio 0.43 0.001
112 M.a.k.a. wahab et al.There is signiﬁcant positive correlation between anti-CCP
and carotid IMT (Table 9) while anti-CCP is signiﬁcantly
negatively correlated with FMD as well as dilatation ratio
(Table 10).
5. Discussion
In the past 20 years, the life expectancy of patients
with rheumatoid arthritis (RA) has been shown to be reducedby three to ten years as compared to that of the general pop-
ulation. Currently, cardiovascular disease (CVD) is the major
cause of death in patients with RA, and acute myocardial
infarction can be up to four times more frequent in these
patients. The autoimmune systemic inﬂammatory response,
along with the presence of metabolic syndrome (MetS),
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atherosclerosis, regardless of age and sex.15
Endothelial dysfunction and atherosclerosis may be sub-
clinical at early stages, and thus the ability to detect them with
non-invasive techniques is crucially important, particularly in
populations at increased risk for cardiovascular disease, such
as those with rheumatoid arthritis. This may allow the identi-
ﬁcation of interventions that may reverse these processes early
on. One of the best non-pharmacological interventions that
may achieve this is physical activity.16
Among imaging techniques, the early determination of
common carotid intima-media thickness (ccIMT), ﬂow-
mediated dilation (FMD), and nitroglycerine-mediated dila-
tion (NMD) may be useful to determine atherosclerosis and
endothelial dysfunction.17
Results of this study showed the comparison between 56
RA patients and 19 controls with respect to ultrasono-
graphic duplex ﬁndings of carotid arteries and the endothe-
lial function; as two markers of subclinical atherosclerosis,
there were overall higher prevalence of premature athero-
sclerosis in RA patients than controls. In the ﬁrst, seventeen
(17) patients have thickened IMT (30.36%) and only three
(3) patients (5.4%) had atherosclerotic plaque while, one
(1) of controls had thickened IMT (5.3%) with no detected
plaque formation.
In addition, the mean IMT was signiﬁcantly higher in RA
patients than our healthy controls (0.57 ± 0.051 versus
0.49 ± 0.072 mm respectively with P= 0.01). Also, FMD
(P= 0.043) and dilatation ratio (P= 0.00 l) were signiﬁcantly
lower in patient than controls.
In accordance with our result, a study by La Montagna
et al. 8 showed that 50% of patients with RA have athero-
sclerosis; mean IMT was 0.75 ± 0.11 mm. The 45 RA patients
were, ranging from 0.56 to 0.99 mm. In the 48 control subjects,
mean IMT was 0.65 ± 0.09 mm ranging from 0.48 to 0.88 mm
(P< 0.001). In addition, other studies, using a control group,
also conﬁrm that the prevalence of the disease is higher in RA
patients than in the controls.18,19
These ﬁndings indicated that accelerated atherosclerosis is a
well deﬁned feature of rheumatoid arthritis in agreement with
many other studies.20–23
Epidemiological studies have used different cut off values
for IMT in the general population. Differences in the site
and method of carotid measurement may account for different
results. In Doria et al. study normal IMT was deﬁned when
complex intima-media is >0.09 mm; therefore, IMT values
0.09 mm were considered indicative of thickened intima 10
while in another study, the subclinical atherosclerosis IMT
cut-off value detected was >0.07 mm.11 In our study as well
as in previous studies24,25,8 intima-media thickness was consid-
ered abnormal if >0.072 mm.
In our study in spite of the presence of accelerated athero-
sclerosis in rheumatoid patients, the prevalence of traditional
cardiovascular risk factors in rheumatoid arthritis patients
and controls was of no signiﬁcant difference. On the other
hand, increased prevalence of insulin resistance in RA com-
pared to controls (p< 0.001) was found, which may be the
factor promoting atherosclerosis.
Furthermore, results of this study revealed that insulin
resistance is signiﬁcantly correlated with IMT and signiﬁcantly
negatively correlated with ﬂow mediated dilatation and dilata-
tion ratio.These results are supported by previous study18 which
found no differences in atherosclerotic risk factors between
patients with RA and controls. However, In the RA group,
the median carotid IMT was signiﬁcantly greater than in con-
trols. They concluded IR in the setting of active rheumatoid
disease may contribute to mechanisms of accelerated
atherogenesis observed in patients with RA.
This is in accordance with Dhawan and Quyyumi26 who
concluded that the increased cardiovascular disease risk in
RA patients seems to be independent of traditional cardio-
vascular risk factors.26 Several other pathogenic mechanisms
include insulin resistance that subsequently leads to endothe-
lial dysfunction, a decrease in endothelial progenitor cells,
and arterial stiffness, which are the congeners of accelerated
atherosclerosis observed in RA patients.
This is similar to previous study found that increased preva-
lence of insulin resistance has been observed in patients with
rheumatoid arthritis.27 Also, other authors concluded that
insulin resistance has been shown to be an independent risk
factor for ischemic heart disease and had long been known
to occur in RA.28
The same result obtained with other authors who showed a
signiﬁcantly higher prevalence of IR in RA patients and
pointed out a signiﬁcant association between IR and
subclinical atherosclerosis.8
In agreement with our results, Chung et al.29 concluded
that patients with RA have a higher prevalence of the meta-
bolic syndrome including insulin resistance than control sub-
jects.29 Inﬂammation-associated metabolic syndrome is a
mechanism that may contribute to increased coronary-artery
atherosclerosis in RA.
Beyond the traditional cardiovascular risk factors, chronic
systemic inﬂammation has been shown to be a crucial factor
in atherosclerosis development and progression from endothe-
lial dysfunction to plaque rupture and thrombosis.30
Inﬂammation disturbs biochemical pathways involved in
homeostasis of the endothelium. Research has established
clear links between inﬂammatory mediators, particularly C-
reactive protein and tumor necrosis factor alpha, with
endothelial dysfunction, and atherosclerosis.16
Inﬂammation is considered to be an important risk factor
for premature atherosclerosis in RA. This was a very consis-
tent ﬁnding in the present study as measured by acute phase
reactants including highly sensitive CRP and erythrocyte sedi-
mentation rate.
Higher levels of ESR (P< 0.001) andCRP (P< 0.001)were
detected in RA compared to healthy controls in agreement with
previous study in which higher levels of ESR (P< 0.001) and
CRP (P< 0.001) also were detected.19 These data deﬁnitely
support systemic inﬂammation as a factor of importance for
premature atherosclerosis in RA patients.
The inﬂammation may be the underling mechanism linking
the insulin resistance with atherosclerosis in rheumatoid arthri-
tis. This explanation is supported by Goshayeshi et al.31 which
concluded that the impact of chronic inﬂammation on athero-
sclerosis and insulin resistance has been observed in several
autoimmune diseases especially in Rheumatoid arthritis
(RA), which is the most common autoimmune arthritis.31
Also, High-grade systemic inﬂammation is implicated in the
development of insulin resistance in these patients.27
Among immunological and metabolic laboratory markers,
anticyclic citrullinated peptide (anti-CCP) antibodies may be
114 M.a.k.a. wahab et al.involved in the development of vascular disease in RA.32 Also in
our study anti-CCP antibodies were positive in forty-seven (47)
patients (83.9%) and ranged from 1 to 312 ng/ml with mean of
85.11 ± 81.98.While in Pereira et al. 19 study anti-CCP antibod-
ies were positively detected in ﬁfty-six (56) RA patients (78.9%),
in Gerli et al.8 study, ﬁfty-two (52) of the eighty-one (81) patients
(64.2%) analyzed tested positive for anti-CCP antibodies.
Anti-CCP positively correlated with ultrasonographic
duplex ﬁndings of IMT of carotid arteries left IMT, mean
IMT, and maximum IMT (P= 0.0001, 0.001 and 0.0001
respectively) but negative correlation was found with parame-
ters which assess the endothelial function of RA patients: post
FMD, FMD percent and dilatation ratio (P= 0.02, 0.005 and
0.001 respectively).
This in agreement with Gerli et al.8, who to our knowledge,
ﬁrst showed an association between anti-CCP and subclinical
atherosclerosis in patients with RA.
In contrast, Pereira et al.19 study showed that although anti-
CCP antibodies have been shown to be signiﬁcantly associated
with RA patients group their association with IMT as subclini-
cal atherosclerosis parameter; was not of signiﬁcant results.
Since previous study has conﬁrmed that anti-TNF-a ther-
apy improves insulin resistance, beta-cell function, and
reverted defects in the insulin signaling cascade in active RA
patients with high insulin resistance,32 we can recommend
other study to verify the effect of this therapy in regression
of subclinical atherosclerosis.
6. Limitations
This study has several limitations. First, the cross-sectional nat-
uremay fail to estimate the truemagnitude of the contribution of
variables, a prospective studymight demonstrate a greater effect
over time and the sample size did not allow evaluation of other
potential predictors of increased IMT in our RA patients.
Another important factor is that although we viewed caro-
tid atherosclerosis as a marker for overall atherosclerotic bur-
den, this disease may progress in other vascular territories
including the coronary circulation, at different rates, and the
results of this study may not be generalizable to atherosclerosis
in other major vascular beds.7. Conclusion
IR and anti-CCP may be helpful in the early detection of sub-
clinical atherosclerosis in RA patients.
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A.1. The 1987 revised American rheumatism association criteria
for rheumatoid arthritis
THE 1958 revision of the American Rheumatism Association’s
(ARA) 1956 criteria for rheumatoid arthritis has now been in
use for some 30 years. This classiﬁcation system has beenaccepted and used by the current generation of rheumatolo-
gists and few studies on RA do not include in their methods
section the statement ‘. . . patients with classical or deﬁnite
RA (ARA criteria) were studied’.
A.1.1. The 1958 criteria, though, have their drawbacks
First, the distinction between classical, deﬁnite andprobableRA
is unhelpful. Few distinguish between classical and deﬁnite and,
as has been pointed out, ’probable RA’ is probably not RA.
Second, since 1958, our understanding of other disease enti-
ties presenting as polyarthritis has changed. Thus the HLA-
B27 related spondarthropathies are not now considered as
seronegative RA and any classiﬁcation system for the latter
would need to make that discrimination.
Third, some of the 1958 criteria, for example mucin clot and
biopsy of subcutaneous nodule, do not reﬂect actual clinical
practice and in reality are not used.
Finally, the individual criteria themselves are fairly loosely
deﬁned, in terms of both nature and duration, and thus there is
anxiety about their low speciﬁcity (the number of false positives).
With these issues inmind theARAcommissioned a sub-com-
mittee in 1983 to produce a revised criteria set for RA.
The results of their deliberations were published in March this
year.
In brief, in the new version there is only one degree of
diagnostic certainty of RA, requiring four of the seven listed
criteria. There is a greater emphasis on involvement of the
wrist and hands (MCP and PIP joints) and the older redundant
features (mucin clots, synovial and nodule biopsy) have been
dropped. In addition the deﬁnition of some of the features
has been hardened, for example morning stiffness has to be
presented for at least 1 h.
The patient database used to generate these criteria was
also analyzed using the method of classiﬁcation trees, a
method previously used in rheumatology in developing criteria
for osteoarthritis.
The results of this analysis are to generate a number of sub-
sets containing combinations of individual criteria.
Two subsets emerged (arthritis, i.e. soft tissue joint swel-
ling, in at least 3/14 candidate joint groups, plus either radio-
graph changes or rheumatoid factor) which in combination
were almost as sensitive (86%) in identifying RA as the value
of 91% for the rule requiring 47 criteria. The addition of a
further three subsets:
1. Arthritis in three joint groups including MCP and wrist.
2. Arthritis in one joint group bilaterally plus rheumatoid
factor.
3. Arthritis of MCP or wrist plus rheumatoid factor, increased
the sensitivity of the classiﬁcation tree derived criteria to
93.5%.
The speciﬁcity was 89% for both classiﬁcation methods
(conventional and subset) against ’consecutive’ attenders with
diseases other than RA.
A.2. British Journal of rheumatology vol. XXVII no. 5
Osteoarthrosis (or SLE). Further, no patient from 137 normal
individuals was positive for RA by either of the classiﬁcation
methods.
Table A.1 Comparison of 1987 with 1958 criteria.
1987 1958
1. Morning stiﬀness in and around joints at least 1 h 1. Morning stiﬀness
2. Soft tissue joint swelling observed by physician at least 3/14 joint groups
(R or L: MCP, PIP, wrist, elbow, knee, ankle, MTP)
2. Swelling of a joint
3. Soft tissue joint swelling in a hand joint (MCP, PIP or wrist) 3. Swelling of another joint
4. Symmetrical swelling of one joint area in (2) above 4. Pain on movement or tenderness in a joint
5. Rheumatoid nodule 5. Symmetrical swelling
6. Rheumatoid factor by method positive in <5% normal population 6. Rheumatoid nodule
7. Radiograph changes on wrist/hands: erosions or juxta-articular osteoporosis 7. Rheumatoid factor
8. Radiograph changes
9. Mucin clot
10. Synovial biopsy
11. Nodule biopsy
RA = 4/7 criteria Classical RA = 7/11 criteria
Deﬁnite RA= 5/11 criteria
Probable RA= 3/11 criteria
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First, the development of alternative formulations may be a
source of confusion. Most clinicians will presumably prefer
the conventional ATI form. As the criteria stand an investiga-
tor could accept RA as either positive for 4/7 criteria or con-
forming to one of the ﬁve subsets. It might be useful for the
ﬁrst few years to specify in any publication which method
was chosen as it could conceivably explain differences in
results between studies.
Second, the patients studied to formulate these criteria were
current attenders with established disease (mean duration 7.7
years), whereas diagnostic criteria are of greatest utility in
early disease. Thus the sensitivity of these criteria at diagnosis
remains unknown.
Third, there are no exclusions, as with the original criteria,
and it appears likely that patients with other inﬂammatory
poly-arthropathies, particularly SLE, psoriatic arthritis and
reactive arthritis, would satisfy the new rules.
In use, therefore, readers would wish to know that these
diseases had been excluded. Further, in populations where
the occurrence of rheumatoid arthritis is reduced relative to
that of other peripheral joint inﬂammatory arthropathies, the
predictive value (proportion of all those satisfying criteria
who have RA) of the criteria in both the clinic and the commu-
nity will be lower than in the US population studied.
Fourth, the exclusion of the shoulder from the list of
involved joints might be a surprise to many, as shoulder
involvement is not a rare event in RA. Despite these draw-
backs the new criteria are a step forward in removing the prob-
lems listed above in the 1958 version. It is accepted that
European investigators will probably have to fall into line
and begin to use these criteria but both indicate which for-
mulation they are using and be aware of the problems of not
excluding other diseases.
Finally, diagnostic criteria have many uses. The clinical tri-
alist will want very speciﬁc criteria whereas the epidemiologist
will also (see Table A.1).
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